HLS Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Craig Millian
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 26.92% |
| CEO tenure | 2yrs |
| CEO ownership | 0.04% |
| Management average tenure | 4.5yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$18m |
| Dec 31 2024 | n/a | n/a | -US$20m |
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$1m | US$381k | -US$28m |
Compensation vs Market: Craig's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD499.93K).
Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.
CEO
Craig Millian (56 yo)
Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$1.41m | 0.040% € 39.9k | |
| CFO & Non-Independent Director | 1.3yrs | US$110.39k | 0.025% € 25.5k | |
| Vice President of Scientific Affairs | 10.9yrs | US$313.47k | 0.16% € 158.6k | |
| Senior VP of Legal | 7yrs | US$418.09k | 0.0016% € 1.6k | |
| Chief Commercial Officer | 1.9yrs | US$437.71k | 0.0038% € 3.8k | |
| Investor Relations Officer | no data | no data | no data | |
| VP & Corporate Controller | 7.3yrs | no data | no data |
Experienced Management: 74D's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$1.41m | 0.040% € 39.9k | |
| CFO & Non-Independent Director | 1.9yrs | US$110.39k | 0.025% € 25.5k | |
| Independent Chairman of the Board | 3.9yrs | US$248.89k | 0.45% € 450.9k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 7.2yrs | US$220.00k | no data | |
| Independent Director | 3.9yrs | US$207.50k | 0.0016% € 1.6k | |
| Independent Director | 2.5yrs | US$209.50k | 0.0056% € 5.6k | |
| Independent Director | 1.9yrs | US$112.49k | no data |
Experienced Board: 74D's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 00:16 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| George Ulybyshev | Clarus Securities Inc. |